The cholinergic and non-cholinergic effects of organophosphates and oximes in cultured human myoblasts

Maja Katalinić1, Katarina Miš, Sergej Pirkmajer

  • 1Institute for Medical Research and Occupational Health, Zagreb, Croatia.

Insights

Organophosphorus compounds and oximes impact muscle cells beyond AChE, affecting IL-6 and HSP 27. Pretreatment with oxime K048 mitigates these non-cholinergic effects in muscle regeneration.

Area of Science:

  • Biochemistry
  • Toxicology
  • Cell Biology

Background:

  • Organophosphorus compounds (OPs) and oximes can exert non-cholinergic effects in biological systems.
  • These effects may influence cellular processes and contribute to clinical outcomes in OP poisoning.
  • Interactions with molecules other than acetylcholinesterase (AChE) warrant investigation.

Purpose of the Study:

  • To investigate the non-cholinergic effects of tabun (an OP) and oxime K048 on human myoblasts.
  • To examine the impact on interleukin-6 (IL-6) secretion and heat shock protein (HSP) 27 levels.
  • To understand the role of these effects in muscle regeneration and myotoxicity.

Main Methods:

  • Experiments conducted on cultured human myoblasts.
  • Treatment with tabun and oxime K048.
  • Analysis of AChE mRNA levels, AChE catalytic activity, IL-6 secretion, and HSP 27 protein levels.

Main Results:

  • Tabun and K048 did not alter AChE mRNA levels but affected AChE activity.
  • Tabun exposure decreased IL-6 secretion by 53% and increased HSP 27 levels by 34%.
  • Oxime K048 pretreatment attenuated these effects; post-treatment did not.

Conclusions:

  • OPs and oximes exhibit non-cholinergic effects on myoblasts, influencing IL-6 and HSP 27.
  • These effects are compound-group specific rather than compound-specific.
  • Understanding these mechanisms is crucial for addressing OP-induced myotoxicity and muscle regeneration.

Related Concept Videos

Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Indirect-Acting Cholinergic Agonists: Pharmacokinetics01:22

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they are...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...